Complete Genomics
Private Company
Total funding raised: $170M
Overview
Complete Genomics is a private company driving innovation in genomics through its proprietary DNBSEQ™ sequencing technology and Stereo-seq spatial transcriptomics platform. It offers a comprehensive suite of solutions, from benchtop to ultra-high-throughput sequencers, kits, reagents, and software, primarily for the research and clinical research markets. The company is strategically focused on establishing WGS as the new clinical gold standard and expanding its ecosystem through key partnerships with service providers and technology integrators.
Technology Platform
DNBSEQ™ technology uses rolling circle replication to create DNA nanoballs (DNBs) for PCR-free, high-accuracy sequencing on a patterned array flow cell. Its Stereo-seq platform enables spatial transcriptomics with nanoscale resolution and a large capture area for tissue-wide analysis.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Complete Genomics primarily competes with Illumina in the NGS instrument market, differentiating on accuracy and cost-per-genome via its DNBSEQ technology. In spatial transcriptomics, it competes with 10x Genomics, Nanostring, and Vizgen, competing on the basis of Stereo-seq's superior resolution and large capture area.